Monte Rosa Therapeutics, Inc. GLUE 深 沪
已收盘 03-27 16:00:00 美东时间
15.38
-0.290
-1.85%
华盛通- 最 高16.07
- 今 开15.75
- 成交量 121.14万股
- 最 低 15.33
- 昨 收 15.67
- 总市值 12.31亿
- 52周最高 25.77
- 市盈率 静 --
- 换手率 1.51%
- 52周最低 3.5001
- 委 比 25.35%
- 总股本 8001.57万
- 历史最高 45.56
- 量 比 0.58
- 振 幅 4.72%
- 历史最低 2.44
- 每 手 1
- 风险率 6.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Monte Rosa Therapeutics Q4 EPS $(0.55) Misses $(0.33) Estimate, Sales $2.781M Miss $15.506M Estimate
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.33) by 65.17 percent. This is a 339.13 percent decrease over earnings of $0.23 per
03-17 20:10
Monte Rosa Enters Into Supply Agreement With Johnson & Johnson To Evaluate MRT-2359 In Combination With ERLEADA For Treatment Of Patients With mCRPC With AR Mutations In Planned Phase 2 Study Expected To Initiate In Q3 Of 2026
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreated
03-16 19:06
Monte Rosa Highlights Updated Phase 1/2 Data Showing 67% Overall RECIST Disease Control And Tumor Reductions In Heavily Pretreated mCRPC
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2
02-24 20:19
美股大行评级 | 英特尔、美光科技、SanDisk等获大行上调目标价；纽约梅隆银行获5家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Rezolve AI"买入"评级，目标价从10美元升至12美元；HC Wainwright & Co.：维持Largo"买入"评级，目标价从2.9美元升至3.1美元
01-15 16:10
Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Raises Price Target to $37
Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $27.5 to $37.
01-14 22:49
美股周涨跌榜 | 脑再生科技涨超120%，马斯克“量产预告”催化脑机概念行情；Alumis周涨近120%
ANPA周涨近300%，公司获私募大额股份认购；脑再生科技涨超120%，马斯克“量产预告”催化脑机概念行情；Alumis周涨近120%，治疗银屑病新药临床成功>>
01-10 06:27
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
美股牛股 | 脑机接口概念持续强势！脑再生科技大涨超60%；Revolution涨超28.6%
脑机接口概念持续强势！脑再生科技大涨超60%，近四日涨幅超150%；“收购传闻”引股价过山车，Revolution隔夜涨超28.6%，盘后跌超6%>>
01-08 15:53
